David A Stevens

List of Publications by Year in Descending Order

250 papers	20,413 citations	58 h-index	139 g-index
259 ext. papers	22,851 ext. citations	5.8 avg, IF	6.45 L-index

#	Paper	IF	Citations
250	Synergy Between Filtrates And Voriconazole Against Biofilm Is Less for Mucoid Isolates From Persons With Cystic Fibrosis.. *Frontiers in Cellular and Infection Microbiology*, **2022**, 12, 817315	5.9	
249	FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs. *Clinical Infectious Diseases*, **2021**,	11.6	1
248	Altered Strategies to Inhibit Surface Colonies. *Frontiers in Cellular and Infection Microbiology*, **2021**, 11, 734296	5.9	2
247	Molecular Modifications of the Pseudomonas Quinolone Signal in the Intermicrobial Competition with. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	2
246	Virulence Factors Support Voriconazole Effects on. *Pathogens*, **2021**, 10,	4.5	1
245	Virus Infection of Compromises the Fungus in Intermicrobial Competition. *Viruses*, **2021**, 13,	6.2	2
244	Concurrent Pseudohyperaldosteronism and Primary Glucocorticoid Deficiency From Posaconazole. *Journal of the Endocrine Society*, **2021**, 5, A124-A125	0.4	
243	Molecular epidemiology of aspergillosis in Magellanic penguins and susceptibility patterns of clinical isolates. *Medical Mycology*, **2021**, 59, 1076-1084	3.9	2
242	Under nonlimiting iron conditions pyocyanin is a major antifungal molecule, and differences between prototypic Pseudomonas aeruginosa strains. *Medical Mycology*, **2021**, 59, 453-464	3.9	7
241	In vitro anti-Cryptococcus activity of diphenyl diselenide alone and in combination with amphotericin B and fluconazole. *Brazilian Journal of Microbiology*, **2021**, 52, 1719-1723	2.2	
240	Severe Posaconazole-Induced Glucocorticoid Deficiency with Concurrent Pseudohyperaldosteronism: An Unfortunate Two-for-One Special. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	2
239	Efficacy of nikkomycin Z in murine CNS coccidioidomycosis: modelling sustained-release dosing. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2629-2635	5.1	2
238	Coinfection of disseminated cryptococcosis and BK Virus, a casualty of missed diagnosis during the COVID-19 Pandemic: A case report and review of the literature.. *Current Medical Mycology*, **2021**, 7, 44-49	1.1	1
237	and co-infection in an immunocompromised patient: Case report and literature review. *Medical Mycology Case Reports*, **2020**, 28, 29-32	1.7	1
236	Aspergillosis in free-ranging aquatic birds. *Medical Mycology Case Reports*, **2020**, 28, 36-38	1.7	6
235	Completion of the sequence of the Aspergillus fumigatus partitivirus 1 genome. *Archives of Virology*, **2020**, 165, 1891-1894	2.6	1
234	Review of Potential Weaponry, Relevant to the Interplay, for the Mycology Community. *Journal of Fungi (Basel, Switzerland)*, **2020**, 6,	5.6	20

233	The Pseudomonas aeruginosa product pyochelin interferes with Trypanosoma cruzi infection and multiplication in vitro. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **2020**, 114, 492-498	2	1
232	Disseminated sporotrichosis with immune reconstitution inflammatory syndrome in an HIV patient: Case report and review of the literature. *Revista Iberoamericana De Micologia*, **2020**, 37, 97-99	1.6	2
231	Novel intermicrobial molecular interaction: Quinolone Signal (PQS) modulates response to iron. *Microbiology (United Kingdom)*, **2020**, 166, 44-55	2.9	19
230	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clinical Infectious Diseases*, **2020**, 71, 1367-1376	11.6	607
229	Aspergillosis in albatrosses. *Medical Mycology*, **2020**, 58, 852-855	3.9	3
228	Live imaging and quantitative analysis of growth and morphology during inter-microbial interaction with. *Virulence*, **2020**, 11, 1329-1336	4.7	1
227	Comparative Study of Newer and Established Methods of Diagnosing Coccidioidal Meningitis. *Journal of Fungi (Basel, Switzerland)*, **2020**, 6,	5.6	1
226	Is Inhibited by Volatiles. *Journal of Fungi (Basel, Switzerland)*, **2020**, 6,	5.6	4
225	Aspergillosis, Avian Species and the One Health Perspective: The Possible Importance of Birds in Azole Resistance. *Microorganisms*, **2020**, 8,	4.9	10
224	Intermicrobial interaction: Aspergillus fumigatus siderophores protect against competition by Pseudomonas aeruginosa. *PLoS ONE*, **2019**, 14, e0216085	3.7	31
223	Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection. *Stem Cell Reports*, **2019**, 12, 1232-1241	8	15
222	The role of occupational Aspergillus exposure in the development of diseases. *Medical Mycology*, **2019**, 57, S196-S205	3.9	20
221	Aspergillus-Pseudomonas interaction, relevant to competition in airways. *Medical Mycology*, **2019**, 57, S228-S232	3.9	26
220	A Combination of Itraconazole and Amiodarone Is Highly Effective against Infection of Human Stem Cell-Derived Cardiomyocytes. *American Journal of Tropical Medicine and Hygiene*, **2019**, 101, 383-391	3.2	11
219	Molecular identification of clinical and environmental avian Aspergillus isolates. *Archives of Microbiology*, **2019**, 201, 253-257	3	14
218	Microhemorrhage-associated tissue iron enhances the risk for invasion in a mouse model of airway transplantation. *Science Translational Medicine*, **2018**, 10,	17.5	18
217	RNA-Seq Profile Reveals Th-1 and Th-17-Type of Immune Responses in Mice Infected Systemically with Aspergillus fumigatus. *Mycopathologia*, **2018**, 183, 645-658	2.9	9
216	Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature. *Diagnostic Microbiology and Infectious Disease*, **2018**, 91, 147-152	2.9	37

215	Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of Aspergillus fumigatus Biofilm. *Journal of Bacteriology*, **2018**, 200,	3.5	62
214	Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm. *Mycopathologia*, **2018**, 183, 263-272	2.9	13
213	Iron: an essential nutrient for Aspergillus fumigatus and a fulcrum for pathogenesis. *Current Opinion in Infectious Diseases*, **2018**, 31, 506-511	5.4	19
212	Susceptibility of Candida albicans from Cystic Fibrosis Patients. *Mycopathologia*, **2017**, 182, 863-867	2.9	1
211	Effect of Anaerobiasis or Hypoxia on Pseudomonas aeruginosa Inhibition of Aspergillus fumigatus Biofilm. *Archives of Microbiology*, **2017**, 199, 881-890	3	16
210	Visualization of Aspergillus fumigatus biofilms with Scanning Electron Microscopy and Variable Pressure-Scanning Electron Microscopy: A comparison of processing techniques. *Journal of Microbiological Methods*, **2017**, 132, 46-55	2.8	15
209	Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas. *Mycopathologia*, **2017**, 182, 315-318	2.9	10
208	Verapamil Inhibits Aspergillus Biofilm, but Antagonizes Voriconazole. *Journal of Fungi (Basel, Switzerland)*, **2017**, 3,	5.6	4
207	Effect of acute predation with bacteriophage on intermicrobial aggression by Pseudomonas aeruginosa. *PLoS ONE*, **2017**, 12, e0179659	3.7	10
206	Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic Infection in Mice. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 1141-1146	3.2	8
205	Heat-Killed Yeast as a Pan-Fungal Vaccine. *Methods in Molecular Biology*, **2017**, 1625, 23-30	1.4	4
204	Pseudomonas phage inhibition of Candida albicans. *Microbiology (United Kingdom)*, **2017**, 163, 1568-1577	2.9	21
203	Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. *Critical Reviews in Microbiology*, **2016**, 42, 813-46	7.8	28
202	2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. *Clinical Infectious Diseases*, **2016**, 63, e112-46	11.6	270
201	Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. *Clinical Infectious Diseases*, **2016**, 63, 717-22	11.6	53
200	Agar Bioassays for Antifungals in Combination Therapy. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5625	5.9	
199	The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time. *Critical Reviews in Microbiology*, **2016**, 42, 634-42	7.8	22
198	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2180-4	5.9	13

197	Mycologic Endocrinology. *Advances in Experimental Medicine and Biology*, **2016**, 874, 337-63	3.6	5
196	Pf4 bacteriophage produced by Pseudomonas aeruginosa inhibits Aspergillus fumigatus metabolism via iron sequestration. *Microbiology (United Kingdom)*, **2016**, 162, 1583-1594	2.9	44
195	Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins. *Journal of Fungi (Basel, Switzerland)*, **2016**, 2,	5.6	36
194	Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. *PLoS ONE*, **2016**, 11, e0150155	3.7	36
193	Cerebrospinal Fluid (1,3)-Beta-d-Glucan Testing Is Useful in Diagnosis of Coccidioidal Meningitis. *Journal of Clinical Microbiology*, **2016**, 54, 2707-2710	9.7	16
192	Fungal biofilm composition and opportunities in drug discovery. *Future Medicinal Chemistry*, **2016**, 8, 1455-68	4.1	22
191	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2016**, 63, 433-42	11.6	216
190	The brain, amphotericin B, and P-glycoprotein. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1386	5.9	6
189	Analysis of the Aspergillus fumigatus Biofilm Extracellular Matrix by Solid-State Nuclear Magnetic Resonance Spectroscopy. *Eukaryotic Cell*, **2015**, 14, 1064-72		51
188	Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6514-20	5.9	27
187	Evaluating Common Humoral Responses against Fungal Infections with Yeast Protein Microarrays. *Journal of Proteome Research*, **2015**, 14, 3924-31	5.6	7
186	Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2015**, 14, 474-81	4.1	41
185	Aspergillus fumigatus Biofilms: a Comparison of Processing Techniques for Scanning Electron Microscopy of Fungal Mycelium and Extracellular Matrix. *Microscopy and Microanalysis*, **2015**, 21, 935-936	0.5	10
184	Drugs Active against Fungi, Pneumocystis, and Microsporidia **2015**, 479-494.e4		7
183	In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals. *Medical Mycology*, **2015**, 53, 295-301	3.9	31
182	Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. *PLoS ONE*, **2015**, 10, e0134692	3.7	62
181	Whole glucan particles as a vaccine against systemic coccidioidomycosis. *Journal of Medical Microbiology*, **2015**, 64, 1237-1243	3.2	13
180	Whole glucan particles as a vaccine against murine aspergillosis. *Journal of Medical Microbiology*, **2014**, 63, 1750-1759	3.2	23

179	Protection against experimental aspergillosis by heat-killed yeast is not antibody dependent. *Medical Mycology*, **2014**, 52, 422-6	3.9	9
178	Molecular screening of 246 Portuguese Aspergillus isolates among different clinical and environmental sources. *Medical Mycology*, **2014**, 52, 519-29	3.9	43
177	Roussoella percutanea, a novel opportunistic pathogen causing subcutaneous mycoses. *Medical Mycology*, **2014**, 52, 689-98	3.9	25
176	Application of a non-amplification-based technology to detect invasive fungal pathogens. *Diagnostic Microbiology and Infectious Disease*, **2014**, 78, 137-40	2.9	2
175	Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. *Vaccine*, **2014**, 32, 3573-6	4.1	13
174	Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii. *Mycopathologia*, **2014**, 178, 189-95	2.9	12
173	Vitamin D and experimental invasive aspergillosis. *Medical Mycology*, **2014**, 52, 847-52	3.9	4
172	Development and validation of a quantitative real-time PCR assay for the early diagnosis of coccidioidomycosis. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 214-21	2.9	21
171	Microbiology and epidemiology of Halomonas species. *Future Microbiology*, **2013**, 8, 1559-73	2.9	29
170	Mycologic catastrophe. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2904	5.9	1
169	Reflections on the approach to treatment of a mycologic disaster. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1567-72	5.9	15
168	Inflammatory marker profiles in an avian experimental model of aspergillosis. *Medical Mycology*, **2013**, 51, 696-703	3.9	15
167	Halomonas johnsoniae: review of a medically underappreciated genus of growing human importance. *American Journal of the Medical Sciences*, **2013**, 345, 335-8	2.2	6
166	Aspergillus fumigatus invasion increases with progressive airway ischemia. *PLoS ONE*, **2013**, 8, e77136	3.7	32
165	Saccharomyces as a vaccine against systemic candidiasis. *Immunological Investigations*, **2012**, 41, 847-55	2.9	23
164	Advances in systemic antifungal therapy. *Clinics in Dermatology*, **2012**, 30, 657-61	3	8
163	Protein targets for broad-spectrum mycosis vaccines: quantitative proteomic analysis of Aspergillus and Coccidioides and comparisons with other fungal pathogens. *Annals of the New York Academy of Sciences*, **2012**, 1273, 44-51	6.5	16
162	Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4439-49	5.9	27

161	Draft genome sequence of the human pathogen Halomonas stevensii S18214T. *Journal of Bacteriology*, **2012**, 194, 5143	3.5	7
160	Vaccination with mannan protects mice against systemic aspergillosis. *Medical Mycology*, **2012**, 50, 818-28	3.9	24
159	An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 96-128	10.2	388
158	Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. *Vaccine*, **2011**, 29, 1745-53	4.1	49
157	Diagnosing invasive fungal disease in critically ill patients. *Critical Reviews in Microbiology*, **2011**, 37, 277-3[illegible]	7.8	51
156	Hormones and the resistance of women to paracoccidioidomycosis. *Clinical Microbiology Reviews*, **2011**, 24, 296-313	34	78
155	Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. *Medical Mycology*, **2011**, 49, 834-47	3.9	18
154	Real-time PCR and quantitative culture for monitoring of experimental Aspergillus fumigatus intracranial infection in neutropenic mice. *Journal of Medical Microbiology*, **2011**, 60, 913-919	3.2	13
153	Saccharomyces as a vaccine against systemic aspergillosis: Rthe friend of manRa friend again?. *Journal of Medical Microbiology*, **2011**, 60, 1423-1432	3.2	27
152	Developing a vaccine against aspergillosis. *Medical Mycology*, **2011**, 49 Suppl 1, S170-6	3.9	47
151	Influence of 17□estradiol on gene expression of Paracoccidioides during mycelia-to-yeast transition. *PLoS ONE*, **2011**, 6, e28402	3.7	34
150	Aspergillosis in the Rnonimmunocompromised Rhost. *Immunological Investigations*, **2011**, 40, 751-66	2.9	53
149	Efficacy of recombinant human mannose binding lectin alone and in combination with itraconazole against murine Candida albicans vaginitis. *Immunological Investigations*, **2011**, 40, 553-68	2.9	7
148	Immunotherapy for Difficult-to-Treat Invasive Fungal Diseases **2011**, 331-339		
147	Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. *Medical Mycology*, **2010**, 48, 16-28	3.9	37
146	Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. *Medical Mycology*, **2010**, 48, 704-9	3.9	18
145	Resistance of MBL gene-knockout mice to experimental systemic aspergillosis. *Immunology Letters*, **2010**, 128, 105-7	4.1	17
144	Systemic Antifungal Agents **2010**, 549-563		5

143	Genomic DNA microarray comparison of gene expression patterns in Paracoccidioides brasiliensis mycelia and yeasts in vitro. *Microbiology (United Kingdom)*, **2009**, 155, 2795-2808	2.9	26
142	Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1858-62	5.9	25
141	A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. *Journal of Medical Microbiology*, **2009**, 58, 1474-1485	3.2	14
140	Expert opinion: what to do when there is Coccidioides exposure in a laboratory. *Clinical Infectious Diseases*, **2009**, 49, 919-23	11.6	51
139	Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. *Vaccine*, **2009**, 27, 3662-8	4.1	47
138	Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. *Critical Reviews in Microbiology*, **2009**, 35, 283-309	7.8	147
137	Clinical aspergillosis for basic scientists. *Medical Mycology*, **2009**, 47 Suppl 1, S1-4	3.9	6
136	Halomonas, a newly recognized human pathogen causing infections and contamination in a dialysis center: three new species. *Medicine (United States)*, **2009**, 88, 244-249	1.8	46
135	A new method for the treatment of chronic fungal meningitis: continuous infusion into the cerebrospinal fluid for coccidioidal meningitis. *American Journal of the Medical Sciences*, **2009**, 338, 79-82	2.2	8
134	Significant differences in drug susceptibility among species in the Candida parapsilosis group. *Diagnostic Microbiology and Infectious Disease*, **2008**, 62, 106-9	2.9	56
133	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clinical Infectious Diseases*, **2008**, 46, 1813-21	11.6	3744
132	Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2008**, 46, 327-60	11.6	2097
131	A possible mechanism for synergy between antifungal therapy and immune defenses. *Journal of Infectious Diseases*, **2008**, 198, 159-62	7	10
130	Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis. *Infection and Immunity*, **2008**, 76, 994-1002	3.7	29
129	Animal models: an important tool in mycology. *Medical Mycology*, **2007**, 45, 657-84	3.9	61
128	Azole therapy of clinical and experimental coccidioidomycosis. *Annals of the New York Academy of Sciences*, **2007**, 1111, 442-54	6.5	9
127	Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 998-1003	5.9	18
126	Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. *Clinical Infectious Diseases*, **2007**, 44, 2-12	11.6	640

125	Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 673-6	5.1	20
124	Posaconazole therapy for chronic refractory coccidioidomycosis. *Chest*, **2007**, 132, 952-8	5.3	91
123	Production of IL-6, in contrast to other cytokines and chemokines, in macrophage innate immune responses: effect of serum and fungal (Blastomyces) challenge. *Cytokine*, **2007**, 39, 163-70	4	14
122	Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them?. *Medical Mycology*, **2006**, 44, S119-S126	3.9	31
121	Susceptibility to pulmonary blastomycosis in young compared to adult mice: immune deficiencies in young mice. *Medical Mycology*, **2006**, 44, 51-60	3.9	7
120	Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 1293-7	5.9	89
119	Th1/Th2 in aspergillosis. *Medical Mycology*, **2006**, 44, S229-S235	3.9	33
118	Interferon- gamma as an antifungal. *Journal of Infectious Diseases*, **2006**, 194 Suppl 1, S33-7	7	27
117	Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 3160-1	5.9	165
116	Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D. *Infection and Immunity*, **2006**, 74, 4549-56	3.7	32
115	Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2650-7	5.9	36
114	Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. *Journal of Infectious Diseases*, **2006**, 193, 1023-8	7	21
113	Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. *Journal of Antimicrobial Chemotherapy*, **2006**, 58, 466-9	5.1	31
112	IL-12 induction of resistance to pulmonary blastomycosis. *Cytokine*, **2006**, 35, 221-8	4	2
111	Immunological basis for susceptibility and resistance to pulmonary blastomycosis in mouse strains. *Cytokine*, **2005**, 32, 12-9	4	9
110	Studies of the paradoxical effect of caspofungin at high drug concentrations. *Diagnostic Microbiology and Infectious Disease*, **2005**, 51, 173-8	2.9	94
109	Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1369-76	5.9	42
108	Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 4867-75	5.9	124

107	Coccidioidomycosis. *Clinical Infectious Diseases*, **2005**, 41, 1217-23	11.6	515
106	Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. *Journal of Antimicrobial Chemotherapy*, **2005**, 56, 166-71	5.1	26
105	Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. *Infection and Immunity*, **2004**, 72, 2338-49	3.7	46
104	Efficacy of posaconazole in a murine model of central nervous system aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 4063-6	5.9	46
103	Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 3407-11	5.9	184
102	Vaccinate against aspergillosis! A call to arms of the immune system. *Clinical Infectious Diseases*, **2004**, 38, 1131-6	11.6	43
101	Azoles in the Management of Systemic Fungal Infections. *Infectious Diseases in Clinical Practice*, **2004**, 12, 81-92	0.2	2
100	Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. *Infection and Immunity*, **2004**, 72, 4878-80	3.7	32
99	Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. *Microbes and Infection*, **2004**, 6, 383-9	9.3	24
98	Effects of Interferon-□Gene Therapy in the Murine Central Nervous System and Concentrations in Cerebrospinal Fluid after Intrathecal or Intracerebral Administration. *Biotechnology*, **2004**, 4, 11-18	0.1	4
97	Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. *Clinical Infectious Diseases*, **2003**, 37 Suppl 3, S225-64	11.6	506
96	Antifungal drug resistance. *Clinical Infectious Diseases*, **2003**, 36, S31-41	11.6	170
95	Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. *Clinical Infectious Diseases*, **2003**, 37 Suppl 3, S157-87	11.6	118
94	Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. *Clinical Infectious Diseases*, **2003**, 37 Suppl 3, S188-224	11.6	146
93	Coccidioidomycosis. *Infectious Disease Clinics of North America*, **2003**, 17, 41-57, viii	6.5	185
92	Caspofungin. *Clinical Infectious Diseases*, **2003**, 36, 1445-57	11.6	278
91	Efficacy of micafungin alone or in combination against systemic murine aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 1452-5	5.9	80
90	Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 813-5	5.9	29

89	Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. *Journal of Infectious Diseases*, **2003**, 187, 705-9	7	48
88	Protection of peritoneal macrophages by granulocyte/macrophage colony-stimulating factor (GM-CSF) against dexamethasone suppression of killing of Aspergillus, and the effect of human GM-CSF. *Microbes and Infection*, **2002**, 4, 133-8	9.3	15
87	Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 2420-6	5.9	72
86	Development of a murine model of cerebral aspergillosis. *Journal of Infectious Diseases*, **2002**, 186, 574-7	7	42
85	Resistance mechanisms in clinical isolates of Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1704-13	5.9	369
84	Diagnosis of fungal infections: current status. *Journal of Antimicrobial Chemotherapy*, **2002**, 49 Suppl 1, 11-9	5.1	161
83	Regulation of bronchoalveolar macrophage proinflammatory cytokine production by dexamethasone and granulocyte-macrophage colony-stimulating factor after stimulation by Aspergillus conidia or lipopolysaccharide. *Cytokine*, **2002**, 19, 14-20	4	23
82	Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model. *Journal of Antimicrobial Chemotherapy*, **2002**, 50, 361-4	5.1	22
81	Homozygosity at the Candida albicans MTL locus associated with azole resistance. *Microbiology (United Kingdom)*, **2002**, 148, 1061-1072	2.9	84
80	Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis. *Microbes and Infection*, **2001**, 3, 3-10	9.3	16
79	Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 686-9	5.9	42
78	The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. *Diagnostic Microbiology and Infectious Disease*, **2001**, 39, 99-103	2.9	50
77	Current pharmacotherapy of allergic bronchopulmonary aspergillosis. *Expert Opinion on Pharmacotherapy*, **2001**, 2, 1065-71	4	15
76	Experimental histoplasmosis in mice treated with anti-murine interferon-gamma antibody and in interferon-gamma gene knockout mice. *Microbes and Infection*, **2000**, 2, 997-1001	9.3	28
75	Correlation of susceptibility of immature mice to fungal infection (blastomycosis) and effector cell function. *Infection and Immunity*, **2000**, 68, 6833-9	3.7	7
74	Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 2547-8	5.9	58
73	A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. *New England Journal of Medicine*, **2000**, 342, 756-62	59.2	400
72	Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. *Journal of Antimicrobial Chemotherapy*, **2000**, 46, 437-42	5.1	50

71	Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 3302-5	5.9	38
70	Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 1512-7	5.9	35
69	Molecular epidemiology of the global and temporal diversity of Candida albicans. *Clinical Infectious Diseases*, **1999**, 29, 1220-5	11.6	49
68	Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. *Journal of Antimicrobial Chemotherapy*, **1999**, 43, 491-6	5.1	19
67	Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications. *Mycopathologia*, **1999**, 146, 1-8	2.9	20
66	Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis. *Mycopathologia*, **1999**, 146, 53-65	2.9	15
65	Itraconazole in cyclodextrin solution. *Pharmacotherapy*, **1999**, 19, 603-11	5.8	95
64	Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. *Infection and Immunity*, **1999**, 67, 2935-40	3.7	44
63	Combination immunotherapy and antifungal chemotherapy. *Clinical Infectious Diseases*, **1998**, 26, 1266-9	11.6	84
62	Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 2299-303	5.9	60
61	Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 907-10	5.9	54
60	In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 767-71	5.9	62
59	Morphological transition of Paracoccidioides brasiliensis conidia to yeast cells: in vivo inhibition in females. *Infection and Immunity*, **1998**, 66, 5587-91	3.7	52
58	Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypic method. *Journal of Clinical Microbiology*, **1998**, 36, 557-62	9.7	46
57	Analysis of Compassionate Use Itraconazole Therapy for Invasive Aspergillosis by the NIAID Mycoses Study Group Criteria. *Archives of Internal Medicine*, **1997**, 157, 1857		61
56	In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole. *Diagnostic Microbiology and Infectious Disease*, **1997**, 29, 103-6	2.9	21
55	Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocyte-derived macrophages. *Mycopathologia*, **1997**, 138, 29-35	2.9	15
54	Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. *Diagnostic Microbiology and Infectious Disease*, **1996**, 26, 145-8	2.9	12

53	Synergy of human neutrophils with fluconazole in killing Candida species. *Mycopathologia*, **1996**, 134, 115-20	2.9	19
52	Study of the role of iron in the anticryptococcal activity of human serum and fluconazole. *Mycopathologia*, **1996**, 133, 71-7	2.9	12
51	Induction of novel protein synthesis by opsonized Histoplasma capsulatum ingested by murine peritoneal macrophages. *Mycopathologia*, **1995**, 129, 65-72	2.9	3
50	Synergy of fluconazole with macrophages for antifungal activity against Candida albicans. *Mycopathologia*, **1995**, 132, 123-8	2.9	6
49	In vivo and in vitro effects of macrophage colony-stimulating factor (M-CSF) on bronchoalveolar macrophages for antihistoplasmal activity. *International Journal of Immunopharmacology*, **1995**, 17, 49-53		11
48	Macrophage colony-stimulating factor (M-CSF) induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: synergy with fluconazole for killing. *Cellular Immunology*, **1995**, 164, 113-8	4.4	16
47	Coccidioidomycosis. *New England Journal of Medicine*, **1995**, 332, 1077-82	59.2	335
46	Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species. *Journal of Infectious Diseases*, **1995**, 172, 1620-3	7	22
45	Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. *American Journal of Medicine*, **1995**, 98, 249-56	2.4	113
44	Itraconazole and fluconazole for treatment of coccidioidomycosis. *Clinical Infectious Diseases*, **1994**, 18, 470	11.6	7
43	Anticryptococcal activity of macrophages: role of mouse strain, C5, contact, phagocytosis, and L-arginine. *Cellular Immunology*, **1994**, 157, 1-10	4.4	25
42	NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. *American Journal of Medicine*, **1994**, 97, 135-44	2.4	412
41	Management of systemic manifestations of fungal disease in patients with AIDS. *Journal of the American Academy of Dermatology*, **1994**, 31, S64-7	4.5	12
40	Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. *American Journal of Medicine*, **1993**, 95, 279-85	2.4	122
39	Ubiquinone systems of Coccidioides immitis, the causative agent of coccidioidomycosis. *FEMS Microbiology Letters*, **1993**, 108, 243-5	2.9	5
38	Fluconazole-resistant Candida in AIDS patients. Report of two cases. *Oral Surgery, Oral Medicine, and Oral Pathology*, **1993**, 76, 711-5		45
37	IL-4, IgE, and interferon-gamma production in pulmonary blastomycosis: comparison in mice untreated, immunized, or treated with an antifungal (SCH 39304). *Cellular Immunology*, **1993**, 149, 258-67	4.4	23
36	A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. *Clinical Infectious Diseases*, **1992**, 14 Suppl 1, S68-76	11.6	112

35	In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. *Diagnostic Microbiology and Infectious Disease*, **1992**, 15, 21-34	2.9	119
34	Pulmonary aspergillosis in the acquired immunodeficiency syndrome. *New England Journal of Medicine*, **1991**, 324, 654-62	59.2	420
33	Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. *The American Review of Respiratory Disease*, **1991**, 144, 552-6		221
32	Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. *Chest*, **1991**, 100, 813-9	5.3	181
31	Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. *American Journal of Medicine*, **1991**, 91, 267-72	2.4	195
30	Treatment of coccidioidal meningitis with fluconazole. *Clinical Infectious Diseases*, **1990**, 12 Suppl 3, S380-9	11.6	64
29	Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. *Journal of the American Academy of Dermatology*, **1990**, 23, 593-601	4.5	75
28	Itraconazole treatment of phaeohyphomycosis. *Journal of the American Academy of Dermatology*, **1990**, 23, 577-86	4.5	215
27	Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. *American Journal of Medicine*, **1990**, 89, 282-90	2.4	151
26	Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. *Clinical Infectious Diseases*, **1990**, 12, 1147-201	11.6	663
25	Oral Itraconazole Therapy of Cryptococcal Meningitis and Cryptococcosis in Patients with AIDS **1990**, 305-324		9
24	The interface of mycology and endocrinology. *Medical Mycology*, **1989**, 27, 133-40	3.9	21
23	Enhanced killing of Blastomyces dermatitidis by gamma interferon-activated murine peripheral blood polymorphonuclear neutrophils. *International Journal of Immunopharmacology*, **1989**, 11, 855-62		8
22	Gamma-interferon activation of macrophages for killing of Paracoccidioides brasiliensis and evidence for nonoxidative mechanisms. *International Journal of Immunopharmacology*, **1988**, 10, 945-52		62
21	Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. *American Journal of Medicine*, **1988**, 84, 603-10	2.4	86
20	Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. *Clinical Infectious Diseases*, **1987**, 9 Suppl 1, S77-86	11.6	60
19	Activation of murine polymorphonuclear neutrophils for fungicidal activity by recombinant gamma interferon. *Journal of Leukocyte Biology*, **1987**, 41, 434-40	6.5	45
18	Mechanisms in opposite modulation of spleen cell and lymph node cell responses to mitogens following muramyl dipeptide treatment in vivo. *Cellular Immunology*, **1985**, 91, 505-14	4.4	5

17	Candida rugosa in immunocompromised infection. Case reports, drug susceptibility, and review of the literature. *Cancer*, **1985**, 56, 318-20	6.4	29
16	Ketoconazole Metamorphosis. *Archives of Internal Medicine*, **1985**, 145, 813		22
15	Immunological activation of polymorphonuclear neutrophils for fungal killing: studies with murine cells and blastomyces dermatitidis in vitro. *Journal of Leukocyte Biology*, **1984**, 36, 505-20	6.5	25
14	The iron-hydrogen peroxide-iodide system is fungicidal: activity against the yeast phase of Blastomyces dermatitidis. *Journal of Leukocyte Biology*, **1984**, 36, 545-8	6.5	12
13	Coccidioidomycosis and the indications for chemotherapy. *Drugs*, **1983**, 26, 334-6	12.1	7
12	Miconazole in the treatment of coccidioidomycosis. *Drugs*, **1983**, 26, 347-54	12.1	38
11	Ketoconazole binds to the intracellular corticosteroid-binding protein in Candida albicans. *Biochemical and Biophysical Research Communications*, **1983**, 117, 43-50	3.4	17
10	Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. *American Journal of Medicine*, **1983**, 74, 58-63	2.4	58
9	Murine pulmonary macrophages: evaluation of lung lavage fluids, miniaturized monolayers, and candidacidal activity. *The American Review of Respiratory Disease*, **1983**, 127, 110-2		39
8	A cephalosporin active in vivo against Nocardia: efficacy of cefotaxime in murine model of acute pulmonary nocardiosis. *The Journal of Hygiene*, **1983**, 91, 421-7		9
7	Protection against pulmonary blastomycosis: adoptive transfer with T lymphocytes, but not serum, from resistant mice. *Cellular Immunology*, **1982**, 73, 349-59	4.4	37
6	Opposite modulation of lymph node cell and spleen cell responses to mitogens by muramyl dipeptide and its desmethyl analog. *Cellular Immunology*, **1981**, 59, 195-204	4.4	9
5	Endogenous coccidioidal endophthalmitis. *Ophthalmology*, **1980**, 87, 974-84	7.3	34
4	Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. *American Journal of Medicine*, **1976**, 61, 632-40	2.4	131
3	Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. *Antimicrobial Agents and Chemotherapy*, **1976**, 10, 721-8	5.9	143
2	Cryptococcosis in Experimental Animals: Lessons Learned473-488		1
1	Fungal Bloodstream Co-infection by Trichosporon asahii in a COVID-19 Critical Patient: Case Report and Literature Review. *Mycopathologia*,	2.9	0